The American Journal of Pathology announced in a press release that a peer-reviewed scientific article about Vascular BioSciences' CAR peptide "A Novel Vascular Homing Peptide Strategy to Selectively Enhance Pulmonary Drug Efficacy in Pulmonary Arterial Hypertension" is the featured highlight article in the current February 2014 issue of The American Journal of Pathology, Volume 184, Number 2.
Vascular BioSciences announces the e-publication of "A Novel Vascular Homing Peptide Strategy to Selectively Enhance Pulmonary Drug Efficacy in Pulmonary Arterial Hypertension" to be published in the upcoming issue of the American Journal of Pathology, Volume 184, Number 2, February 2014 by Michie Toba, Abdallah Alzoubi, Kealan O'Neill, Kohtaro Abe, Takeo Urakami, Masanobu Komatsu, Diego Alvarez.
Vascular BioSciences (VBS) announced the award of a $1.2 million, milestone-based, 3-year contract from the National Heart Lung Blood Institute (NHLBI) of the National Institutes of Health (NIH) to expedite the development of CAR therapeutic peptide for pulmonary hypertension under NHLBI's Vascular Interventions/Innovations and Therapeutic Advances (VITA) program.
Vascular BioSciences (VBS) announces it will be presenting at a National Heart Lung and Blood Institute (NHLBI) conference on June 11, 2013, from 10:30 to 5pm at the Janssen Research & Development Labs, 3210 Merryfield Row, San Diego CA 92130.
Vascular BioSciences announces the publication of "Vascular Histomolecular Analysis By Sequential Endoarterial Biopsy in a Shunt Model of Pulmonary Hypertension" to the current issue of the Pulmonary Circulation, Volume 3, Number 1, January to March 2013. Details how percutaneous pulmonary endoarterial biopsy coupled with histologic and molecular analysis represents a potential model of diagnosis.
Vascular BioSciences was recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant.
Vascular BioSciences announces CEO David Mann will present "CAR Peptide, a Disease Selective Therapeutic Adjuvant For Targeted Drug Therapy" during the 7th Annual Therapeutic Peptide Symposium to be hosted at The Salk Institute in La Jolla, CA on October 25th and 26th, 2012.
VBS announces the publication of a scientific article which describes the use of an experimental endoarterial biopsy catheter to describe the hemodynamic, angiographic, and histologic progression of an aortopulmonary shunt model of PAH.
A recently published paper from Vascular Biosciences (VBS) has been selected by the Faculty of 1000 (F1000) as one of the top 2 percent of all published articles in the biological and medical sciences in 2011.
VBS Pharmaceuticals announces the publication of a peer-reviewed scientific article that describes a novel peptide that specifically targets and penetrates the vasculature of lungs affected by pulmonary arterial hypertension (PAH) in the current issue of the American Journal of Pathology.
Satisfied Users & 
Approved Press Releases
